Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
End Stage Renal Disease: early-phase trial registry
25 of 88 indexed End Stage Renal Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #156 of 28,707 conditions by registered trial count.
88 US clinical trials · 25 currently recruiting · #156 of 28,707 conditions by registered trial count
End Stage Renal Disease: 88 US clinical trials tracked, 25 recruiting.
End Stage Renal Disease is the subject of 88 registered US clinical trials on ClinicalTrials.gov, 25 of them currently open to new participants. 16 are in Phase 3-4 (later-stage) and 27 in Phase 1-2 (earlier-stage). The most active sponsor is Vanderbilt University, running 4 of these trials.
Enrollment posture brief
Registry condition end-stage-renal-disease
OPEN 25 | RECR 28% | LATE 16 | EARLY 27 | RANK #156 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Acne Scars (29% recruiting · 7 trials)
End Stage Renal Disease lists 25 open slots (28% of 88 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for End Stage Renal Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
End Stage Renal Disease is recruiting below its size-band peers.
25 of 88 indexed trials (28.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of End Stage Renal Disease trials is spread across many organizations.
Vanderbilt University accounts for 4 of 88 trials (4.5%). 69 distinct sponsors appear on at least one study for this condition label.
-
Typical End Stage Renal Disease enrolment sits around 69 participants.
Median target enrolment is 69 among the 87 trials that report a genuine target (sentinel values excluded). 50 of those (57.5%) plan for fewer than 100 participants.
-
End Stage Renal Disease research is mostly interventional.
74 interventional and 14 observational studies make up this index (84.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
88 total, page 2 of 2
Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD
Medtronic Endovascular
NCT02363972
An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000935
Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation
Wright State University
NCT00906204
Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions
Treatment Research Institute
NCT02059005
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
Ardelyx
NCT01764854
A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis
Abbott
NCT00646035
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
Cedars-Sinai Medical Center
NCT02134314
End-Stage Renal Disease Intra-dialysis Lifestyle Education Study
Vanderbilt University Medical Center
NCT02361268
A Study Evaluating the Association of Inflammation With Hemodialysis Access Type
Montefiore Medical Center
NCT01011985
Effects of Hemodialysis on the Sleep/Wake Cycle
Emory University
NCT00460863
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
NxStage Medical
NCT00667511
Effects of Oral Cholecalciferol (Vitamin D3) on Bone Health, Neuromuscular Function, and Quality of Life in Adults With Chronic Kidney Disease
Creighton University
NCT00511225
A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin
Cumberland Pharmaceuticals
NCT01238796
Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
Stanley Jordan, MD
NCT01178216
Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation
University of Miami
NCT01046955
Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients
Duke University
NCT03781089
A Comparison of Physical Activity Levels With and Without Feedback Via Fitbit® Flex™ in Hemodialysis Patients
Renal Research Institute
NCT02320513
Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients
Vanderbilt University
NCT00420290
The Effects of Protein Supplementation and Resistance Exercise in Hemodialysis Patients
Vanderbilt University
NCT00179140
Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.
Rockwell Medical Technologies
NCT04409132
CellCept/Iron Study: The Iron Ion-Mycophenolate Mofetil Chelation Complex Interaction in Renal Allograft Recipients
University of Michigan
NCT00227045
The Effects of Resistance Exercise and Protein Supplementation in Hemodialysis Patients
Vanderbilt University
NCT00179218
Treatment Modification to Reduce Symptom Burden in Hemodialysis
The Rogosin Institute
NCT01775800
Study to Evaluate Daptomycin Given During Dialysis and After Dialysis
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT00882557
Safety and Dose Finding Study of Xigris in Hemodialysis Patients
George Washington University
NCT01227187
First Evaluation of the Moda-Flx Hemodialysis System™ in Real World Clinical Settings
Diality
NCT06581393
Triferic AVNU Infusion Via Freedom Pump During Hemodialysis
Rockwell Medical Technologies
NCT04689932
Acid-Base Composition With Use of hemoDialysates
Fresenius Medical Care North America
NCT02334267
The Effects of Nutrition Supplementation and Resistance Exercise During Hemodialysis
Vanderbilt University
NCT00179179
Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients
Northwestern University
NCT02145325
A Pilot Study Using Autologous Regulatory T Cell Infusion Zortress (Everolimus) in Renal Transplant Recipients
Roberto Gedaly
NCT03284242
A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients
Ochsner Health System
NCT02360748
Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5
University of Michigan
NCT02392208
Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis
Albany College of Pharmacy and Health Sciences
NCT00939952
Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients
Corewell Health East
NCT02159859
Plazomicin Study in ESRD Patients Receiving IHD
Cipla USA
NCT04699656
Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome
Johns Hopkins University
NCT01029587
Prevention of Kidney Transplant Rejection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00005010
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 14 |
| Phase 3 | 7 |
| Phase 4 | 9 |
Top Sponsors
Named interventions
Most-linked intervention names on End Stage Renal Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on End Stage Renal Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this End Stage Renal Disease page
88 registered trials, 25 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 25 End Stage Renal Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Vanderbilt University sponsors the most End Stage Renal Disease trials on record, review their full trial history before evaluating a specific study. See Vanderbilt University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This End Stage Renal Disease condition card totals 88 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.